CytomX Therapeutics, Inc. 8-K

What Happened
CytomX Therapeutics announced unaudited financial results for the three months ended March 31, 2026 in a press release issued May 7, 2026. The company filed an 8‑K (Items 2.02 and 9.01) to furnish that press release, which is included as Exhibit 99.1 to the filing.

Key Details

• Filing date: May 7, 2026; press release titled "CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update."
• Period reported: unaudited results for the three months ended March 31, 2026.
• Exhibit: Press release furnished as Exhibit 99.1 to the Form 8‑K.
• Form 8‑K signed by Christopher W. Ogden, Chief Financial Officer, on May 7, 2026.

Why It Matters
This 8‑K notifies investors that CytomX has released its quarterly financial results and business update; investors should review the furnished press release (Exhibit 99.1) for the actual figures—revenue, expenses, cash position, and any program or guidance updates—because the 8‑K itself only furnishes that press release and does not restate the detailed financials. The results are unaudited, so investors may want to compare with prior quarters and the company’s subsequent filings (e.g., quarterly report on Form 10‑Q) for audited or reconciled figures.